Abstract:Synapses represent an important target of Alzheimer disease (AD), and alterations of their excitability are among the earliest changes associated with AD development. Synaptic activation has been shown to be protective in models of AD, and deep brain stimulation (DBS), a surgical strategy that modulates neuronal activity to treat neurological and psychiatric disorders, produced positive effects in AD patients. However, the molecular mechanisms underlying the protective role(s) of brain stimulation are still elusive. We have previously demonstrated that induction of synaptic activity exerts protection in mouse models of AD and frontotemporal dementia (FTD) by enhancing the macroautophagy/autophagy flux and lysosomal degradation of pathological MAPT/Tau. We now provide evidence that TFEB (transcription factor EB), a master regulator of lysosomal biogenesis and autophagy, is a key mediator of this cellular response. In cultured primary neurons from FTD-transgenic mice, synaptic stimulation inhibits MTORC1 signaling, thus promoting nuclear translocation of TFEB, which, in turn, induces clearance of MAPT/Tau oligomers. Conversely, synaptic activation fails to promote clearance of toxic MAPT/Tau in neurons expressing constitutively active RRAG GTPases, which sequester TFEB in the cytosol, or upon TFEB depletion. Activation of TFEB is also confirmed in vivo in DBS-stimulated AD mice. We also demonstrate that DBS reduces pathological MAPT/Tau and promotes neuroprotection in Parkinson disease patients with tauopathy. Altogether our findings indicate that stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau. This mechanism, underlying the protective effect of DBS, provides encouraging support for the use of synaptic stimulation as a therapeutic treatment against tauopathies.Abbreviations: 3xTg-AD: triple transgenic AD mice; AD: Alzheimer disease; CSA: cyclosporine A; DBS: deep brain stimulation; DIV: days in vitro; EC: entorhinal cortex; FTD: frontotemporal dementia; gLTP: glycine-induced long-term potentiation; GPi: internal segment of the globus pallidus; PD: Parkinson disease; STN: subthalamic nucleus; TFEB: transcription factor EB.

Celastrol, a TFEB (transcription factor EB) agonist, is a promising drug candidate for Alzheimer disease

Celastrol Enhances Transcription Factor EB (Tfeb)-Mediated Autophagy and Mitigates Tau Pathology: Implications for Alzheimer's Disease Therapy

TFEB in Alzheimer's Disease: from Molecular Mechanisms to Therapeutic Implications

Celastrol Attenuates Learning and Memory Deficits in an Alzheimer’s Disease Rat Model

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

A small molecule transcription factor EB activator ameliorates beta‐amyloid precursor protein and Tau pathology in Alzheimer's disease models

HLH-30/TFEB modulates autophagy to improve proteostasis in Aβ transgenic Caenorhabditis elegans

Transcription factor EB: an emerging drug target for neurodegenerative disorders

Novel Insight into Functions of Transcription Factor EB (TFEB) in Alzheimer's Disease and Parkinson's Disease.

TFEB acetylation promotes lysosome biogenesis and ameliorates Alzheimer’s disease–relevant phenotypes in mice

Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB

Celastrol Enhances Cell Viability and Inhibits Amyloid-β Production Induced by Lipopolysaccharide in Vitro

Therapeutic Potential of Vital Transcription Factors in Alzheimer’s and Parkinson’s Disease With Particular Emphasis on Transcription Factor EB Mediated Autophagy

Stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau in cellular and mouse models of tauopathies

Combined targeting of pathways regulating synaptic formation and autophagy attenuates Alzheimer's disease pathology in mice

The Autophagy–Lysosomal Pathway in Neurodegeneration: A TFEB Perspective

Therapeutic Effect of Transmembrane TAT-tCNTF Via Erk and Akt Activation Using in Vitro and in Vivo Models of Alzheimer's Disease.

Corynoxine promotes TFEB/TFE3-mediated autophagy and alleviates Aő≤ pathology in Alzheimer's disease models

TFEB Enhances Astroglial Uptake of Extracellular Tau Species and Reduces Tau Spreading.

Corynoxine Promotes TFEB/TFE3-mediated Autophagy and Alleviates Aβ Pathology in Alzheimer’s Disease Models

Transcription factor EB agonists from natural products for treating human diseases with impaired autophagy-lysosome pathway